{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:29:38Z","timestamp":1762496978115,"version":"build-2065373602"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Current understanding of how immunodeficiencies impact protective responses against viral infections and vaccination is primarily derived from adult cohorts that may not accurately reflect the pediatric, adolescent, and young adult population. This cross-sectional study aimed to evaluate immune responses in this underrepresented population affected by various immunodeficiencies after SARS-CoV-2 infection, two doses of the mRNA BNT162b2 vaccine, or after a combination of both. We analyzed blood samples from 102 immunocompromised patients (IC) (5\u201325 years) categorized into groups of primary immunodeficiencies (PID, n=17), bronchial asthma and allergic rhinitis (BA-AR, n=39), rheumatoid diseases (RD, n=21), and individuals who had undergone hematopoietic stem cell transplantation (HSCT, n=28), as well as 30 healthy individuals (9\u201326 years). We measured titres of Spike-specific IgM, IgA, and IgG antibody classes (including IgG subclasses) in plasma using ELISA and evaluated their inhibitory potential in a Spike-ACE2 cell-based internalization assay. Spike-specific CD4 T-cells were examined using a flow cytometry-based proliferation assay (FASCIA). In the IC group, all participants except eight generated detectable levels of IgG antibodies. The IgG titres induced by vaccination (Geometric mean titre (GMT\n                    <jats:sub>vac<\/jats:sub>\n                    ) = 205023, 95% CI: 116074-362136) and a combination of vaccination and infection (GMT\n                    <jats:sub>hyb<\/jats:sub>\n                    = 172819, 95% CI: 33133-901403) were higher than after infection (GMT\n                    <jats:sub>inf<\/jats:sub>\n                    = 3323, 95% CI: 578-19109, P\n                    <jats:sub>vac\/inf<\/jats:sub>\n                    = .006 and P\n                    <jats:sub>hyb\/inf<\/jats:sub>\n                    = .001). On the other hand, the hybrid immunity induced the highest IgA titres (GMT\n                    <jats:sub>hyb<\/jats:sub>\n                    = 2672, 95% CI: 566-12623) compared to vaccination (GMP\n                    <jats:sub>vac<\/jats:sub>\n                    = 275, 95% CI: 97-777, P\n                    <jats:sub>hyb\/vac<\/jats:sub>\n                    = .016) and infection (GMT\n                    <jats:sub>inf<\/jats:sub>\n                    = 60, 95% CI: 13-280, P\n                    <jats:sub>hyb\/inf<\/jats:sub>\n                    = .002). The IgG titres in vaccinated and hybrid immunity groups strongly correlated (r\n                    <jats:sub>Spearman<\/jats:sub>\n                    = 0.86, P &amp;lt;.0001) with the levels of antibodies inhibiting the internalization of Spike protein (S protein) in a cell-based assay. Most IC patients (except five) also developed above-threshold Spike-specific CD4 T-cell responses, which were not statistically different from the responses in the healthy control group. Our data show that infection and vaccination can induce protective humoral or cellular responses against SARS-CoV-2 in IC patients. The activated cellular response in patients with agammaglobulinemia may assist them in overcoming viral infections.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1661282","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:24:13Z","timestamp":1762496653000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of immunodeficiencies on immunity induced by SARS-CoV-2 infection, mRNA BNT162b2 vaccination, and their combination in children and young adults"],"prefix":"10.3389","volume":"16","author":[{"given":"Lubica","family":"Fialova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birivan","family":"Macek-Nabova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Zilkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Turic-Csokova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denisa","family":"Palova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"Katina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Paulikova-Rolkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ciznar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Horakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubica","family":"Wojciakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Markova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kontsekova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislav","family":"Kovacech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250003","article-title":"Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"1","author":"Poli","year":"2025","journal-title":"J Hum Immun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859019","article-title":"Humoral and cellular responses to BNT162b2 as a booster following two doses of chAdOx1 nCov-19 determined using three SARS-coV-2 antibody assays and an interferon-gamma release assay: A prospective longitudinal study in healthcare workers","volume":"13","author":"Jeong","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2324549","DOI":"10.1080\/21645515.2024.2324549","article-title":"COVID-19 vaccines: Immune correlates and clinical outcomes","volume":"20","author":"Mahrokhian","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/microorganisms13030535","article-title":"SARS-coV-2 vaccine-induced humoral immunity in immunocompetent european adults: A systematic review","volume":"13","author":"Bylica","year":"2025","journal-title":"Microorganisms"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8926","DOI":"10.1038\/s41598-024-59535-0","article-title":"Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults >\/= 50 years: a prospective, observational cohort study","volume":"14","author":"Gaultier","year":"2024","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.04.002","article-title":"Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity","volume":"149","author":"van Leeuwen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae039","article-title":"Follow-up of immune response in patients with common variable immunodeficiency following SARS-CoV-2 vaccination","volume":"217","author":"Gutierrez-Bautista","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"126853","DOI":"10.1016\/j.vaccine.2025.126853","article-title":"Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies","volume":"51","author":"Olivieri","year":"2025","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1390022","article-title":"Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program","volume":"15","author":"van Leeuwen","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2221616","DOI":"10.1001\/jamanetworkopen.2022.21616","article-title":"Long-term immune response to SARS-coV-2 infection among children and adults after mild infection","volume":"5","author":"Di Chiara","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.12.006","article-title":"Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5\u201311 years old children with prior COVID-19","volume":"42","author":"Di Chiara","year":"2024","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.741796","article-title":"Asymptomatic and mild SARS-coV-2 infections elicit lower immune activation and higher specific neutralizing antibodies in children than in adults","volume":"12","author":"Petrara","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"103818","DOI":"10.1016\/j.ebiom.2022.103818","article-title":"Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern","volume":"76","author":"Kovacech","year":"2022","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848586","article-title":"CoVITEST: A fast and reliable method to monitor anti-SARS-coV-2 specific T cells from whole blood","volume":"13","author":"Egri","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.05.010","article-title":"Evaluation of T and B lymphocyte function in clinical practice using a flow cytometry based proliferation assay","volume":"153","author":"Marits","year":"2014","journal-title":"Clin Immunol"},{"key":"B19","volume-title":"R: A language and environment for statistical computing","year":"2024"},{"key":"B20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction to the bootstrap","author":"Efron","year":"1993"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2307\/2347111","article-title":"Algorithm AS 89: the upper tail probabilities of spearman\u2019s rho","volume":"24","author":"Best","year":"1975","journal-title":"J R Stat Soc Ser C Appl Stat."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170882","article-title":"Biallelic Cys141Tyr variant of SEL1L is associated with neurodevelopmental disorders, agammaglobulinemia, and premature death","volume":"134","author":"Weis","year":"2024","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1142918","article-title":"Memory SARS-CoV-2 T-cell response in convalescent COVID-19 patients with undetectable specific IgG antibodies: a comparative study","volume":"14","author":"Fernandez-Moreno","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"113159","DOI":"10.1016\/j.jim.2021.113159","article-title":"A flow cytometry-based proliferation assay for clinical evaluation of T-cell memory against SARS-CoV-2","volume":"499","author":"Lind Enoksson","year":"2021","journal-title":"J Immunol Methods"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.jaci.2022.01.013","article-title":"Comparative analyses of IgG\/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern","volume":"149","author":"Lafon","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1038\/s41467-023-40195-z","article-title":"Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology","volume":"14","author":"de Gier","year":"2023","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100313","DOI":"10.1016\/j.xcrm.2021.100313","article-title":"Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions","volume":"2","author":"Shiakolas","year":"2021","journal-title":"Cell Rep Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/BF02991163","article-title":"IgG4 as a blocking antibody","volume":"1","author":"Aalberse","year":"1983","journal-title":"Clin Rev Allergy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01486-8","article-title":"SARS-coV-2 antibodies in commercial immunoglobulin products show markedly reduced cross-reactivities against omicron variants","volume":"43","author":"Lindahl","year":"2023","journal-title":"J Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934476","article-title":"Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency","volume":"13","author":"Nielsen","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062376","article-title":"Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia","volume":"14","author":"Noto","year":"2023","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01514-7","article-title":"Immune responses 6 months after mRNA-1273 COVID-19 vaccination and the effect of a third vaccination in patients with inborn errors of immunity","volume":"43","author":"van Leeuwen","year":"2023","journal-title":"J Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang","year":"2023","journal-title":"Sci Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1038\/s41467-020-17318-x","article-title":"Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital","volume":"11","author":"Garcia-Basteiro","year":"2020","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1038\/s41598-021-84913-3","article-title":"Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities","volume":"11","author":"Noval","year":"2021","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.24.20042382","article-title":"Viral kinetics and antibody responses in patients with COVID-19","author":"Tan","year":"2020","journal-title":"medRxiv preprint"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1146841","article-title":"Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections","volume":"14","author":"Egri","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.immuni.2022.07.005","article-title":"Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination","volume":"55","author":"Gao","year":"2022","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1527573","article-title":"Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children","volume":"15","author":"Russo","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s00508-024-02459-6","article-title":"Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency: A prospective controlled open-label trial","volume":"136","author":"Vossen","year":"2024","journal-title":"Wien Klin Wochenschr"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01382-7","article-title":"COVID-19 vaccination responses with different vaccine platforms in patients with inborn errors of immunity","volume":"43","author":"Erra","year":"2023","journal-title":"J Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1131604","article-title":"Cellular and humoral immunogenicity of the COVID-19 vaccine and COVID-19 disease severity in individuals with immunodeficiency","volume":"14","author":"Murray","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01133-0","article-title":"SARS-coV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best","volume":"41","author":"Salinas","year":"2021","journal-title":"J Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-coV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses","volume":"44","author":"Zhao","year":"2016","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","author":"Soresina","year":"2020","journal-title":"Pediatr Allergy Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1661282\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:24:14Z","timestamp":1762496654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1661282\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2025.1661282"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1661282","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1661282"}}